MA29925B1 - Composes d'amide de pyrimidine en tant qu'inhibiteurs de pgds - Google Patents

Composes d'amide de pyrimidine en tant qu'inhibiteurs de pgds

Info

Publication number
MA29925B1
MA29925B1 MA30891A MA30891A MA29925B1 MA 29925 B1 MA29925 B1 MA 29925B1 MA 30891 A MA30891 A MA 30891A MA 30891 A MA30891 A MA 30891A MA 29925 B1 MA29925 B1 MA 29925B1
Authority
MA
Morocco
Prior art keywords
amide compounds
compound
pgds inhibitors
pyrimidine amide
pyrimidine
Prior art date
Application number
MA30891A
Other languages
English (en)
Inventor
Suzanne C Aldous
John Ziqi Jiang
Jinqi Lu
Liang Ma
Lan Mu
Harry Randall Munson
Jeffrey Stephen Sabol
Sukanthini Thurairatnam
Christopher Loren Vandeusen
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of MA29925B1 publication Critical patent/MA29925B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne un composé de formule (I) : dans lequel R1, R2, R3 et L1 sont comme présentement définis, une composition pharmaceutique comprenant le composé, et l'utilisation du composé pour traiter des troubles allergiques et/ou inflammatoires, en particulier des troubles tels que la rhinite allergique, l'asthme et/ou la bronchopneumopathie chronique obstructive (COPD).
MA30891A 2005-10-04 2008-05-02 Composes d'amide de pyrimidine en tant qu'inhibiteurs de pgds MA29925B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72357005P 2005-10-04 2005-10-04

Publications (1)

Publication Number Publication Date
MA29925B1 true MA29925B1 (fr) 2008-11-03

Family

ID=37635758

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30891A MA29925B1 (fr) 2005-10-04 2008-05-02 Composes d'amide de pyrimidine en tant qu'inhibiteurs de pgds

Country Status (27)

Country Link
US (1) US8202863B2 (fr)
EP (1) EP1937652B1 (fr)
JP (1) JP5452925B2 (fr)
KR (1) KR101457966B1 (fr)
CN (2) CN101538246B (fr)
AR (1) AR056871A1 (fr)
AU (1) AU2006299428B2 (fr)
BR (1) BRPI0616815A2 (fr)
CA (1) CA2624749C (fr)
CR (1) CR9832A (fr)
DO (1) DOP2006000210A (fr)
EC (1) ECSP088335A (fr)
ES (1) ES2514471T3 (fr)
IL (1) IL190411A (fr)
MA (1) MA29925B1 (fr)
MY (1) MY151172A (fr)
NO (1) NO20082000L (fr)
NZ (1) NZ567208A (fr)
PE (2) PE20110118A1 (fr)
RU (1) RU2420519C2 (fr)
SG (1) SG166121A1 (fr)
TN (1) TNSN08104A1 (fr)
TW (1) TWI415839B (fr)
UA (1) UA93213C2 (fr)
UY (1) UY29840A1 (fr)
WO (1) WO2007041634A1 (fr)
ZA (1) ZA200802222B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759350B2 (en) * 2005-09-15 2010-07-20 Orchid Research Laboratories Ltd. Pyrimidine carboxamides
PE20110118A1 (es) 2005-10-04 2011-03-08 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
CA2648202A1 (fr) 2006-04-11 2007-10-25 Vertex Pharmaceuticals Incorporated Compositions utiles en tant qu'inhibiteurs de canaux sodiques sensibles a la tension
EP2129660A2 (fr) 2006-12-19 2009-12-09 Pfizer Products Inc. Dérivés de nicotinamide en tant qu'inhibiteurs de h-pgds et leur utilisation pour le traitement de maladies liées aux prostaglandines d2
JP2010519328A (ja) 2007-02-26 2010-06-03 ファイザー・プロダクツ・インク Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体およびプロスタグランジンｄ２が媒介する疾患の治療のためのそれらの使用
AU2008293542B9 (en) 2007-08-27 2014-08-07 Dart Neuroscience (Cayman) Ltd. Therapeutic isoxazole compounds
AU2008310661A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Amides useful as inhibitors of voltage-gated sodium channels
CA2702101A1 (fr) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Aryl amides utiles en tant qu'inhibiteurs de canaux sodiques sensibles au voltage
CN101883760A (zh) * 2007-10-11 2010-11-10 沃泰克斯药物股份有限公司 用作电压-门控钠通道抑制剂的杂芳基酰胺类
US8153651B2 (en) * 2007-11-13 2012-04-10 Evotec Ag Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
US8188280B2 (en) * 2008-02-06 2012-05-29 Msd K.K. 3-substituted sulfonyl piperidine derivative
JP2011522524A (ja) * 2008-05-13 2011-08-04 ケイマン ケミカル カンパニー 化合物又は製剤における造血プロスタグランジンｄシンターゼの有力リガンドを置換する能力をアッセイする方法
TW201010997A (en) 2008-06-18 2010-03-16 Pfizer Ltd Nicotinamide derivatives
CA2725481A1 (fr) 2008-06-18 2009-12-23 Pfizer Limited Derives de nicotinamide
US8536185B2 (en) 2008-09-22 2013-09-17 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
KR101252335B1 (ko) 2009-07-16 2013-04-08 (주)아모레퍼시픽 피부 노화 방지용 조성물
WO2010056044A2 (fr) * 2008-11-11 2010-05-20 (주)아모레퍼시픽 Nouveau composé faisant fonction d'antagoniste du récepteur vanilloïde, isomère ou sel pharmaceutiquement acceptable dudit composé, et composition pharmaceutique le contenant
KR101367057B1 (ko) 2009-03-17 2014-02-25 (주)아모레퍼시픽 피부 자극 완화용 조성물
RU2496778C2 (ru) 2009-03-09 2013-10-27 Тайхо Фармасьютикал Ко., Лтд. Пиперазиновое соединение, ингибирующее простагландин-d-синтазу
CN107875155A (zh) * 2009-10-08 2018-04-06 赛诺菲 苯基噁二唑衍生物在制备治疗变应性或炎性疾病的药物中的用途
EP2527340B1 (fr) 2010-01-22 2016-08-17 Taiho Pharmaceutical Co., Ltd. Composé de pipérazine ayant un effet inhibiteur des prostaglandines
US9320723B2 (en) * 2010-05-03 2016-04-26 University Of Rochester Methods of treating thyroid eye disease
US9199976B2 (en) 2010-06-01 2015-12-01 The University Of Queensland Haematopoietic-prostaglandin D2 synthase inhibitors
TW201217335A (en) 2010-09-07 2012-05-01 Taiho Pharmaceutical Co Ltd Prostaglandin d synthase inhibitory piperidine compounds
KR101271223B1 (ko) 2011-01-27 2013-06-07 한국과학기술연구원 아미노피리미딘 유도체 및 이를 포함하는 세포외 신호조절 키나제의 제해제
CA2860672A1 (fr) 2012-01-06 2013-07-11 University Of South Florida Compositions, procedes d'utilisation et procedes de traitement
CN103626752B (zh) * 2012-08-24 2015-08-12 广东东阳光药业有限公司 二氢嘧啶类化合物及其在药物中的应用
CN108430992A (zh) 2015-12-17 2018-08-21 阿斯特克斯医疗公司 作为h-pgds抑制剂的喹啉-3-甲酰胺
WO2017160832A1 (fr) * 2016-03-14 2017-09-21 Emory University Dérivés amide-sulfamide, compositions et utilisations associées à l'inhibition de cxcr4
JOP20190072A1 (ar) 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
EP3638672A1 (fr) 2017-06-13 2020-04-22 GlaxoSmithKline Intellectual Property Development Limited Composés chimiques utilisés en tant qu'inhibiteurs de h-pgds
TWI695000B (zh) * 2017-10-29 2020-06-01 中國醫藥大學 用於抑制ａｄａｍ９活性之化合物、其醫藥組合物及其用途
CA3085293A1 (fr) 2017-12-13 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Pyridines fusionnees agissant en tant qu'inhibiteurs de h-pgds
WO2019179652A1 (fr) * 2018-03-23 2019-09-26 Step Pharma S.A.S. Dérivés d'aminopyrimidine utilisés comme inhibiteurs de ctps1
JP2022506850A (ja) 2018-11-08 2022-01-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 化学化合物
CA3182912A1 (fr) * 2020-05-13 2021-11-18 Chdi Foundation, Inc. Modulateurs htt pour le traitement de la maladie de huntington
WO2021256569A1 (fr) 2020-06-19 2021-12-23 佐藤製薬株式会社 Composés cycliques condensés qui inhibent la h-pgds
US12331046B2 (en) * 2020-10-23 2025-06-17 Nimbus Clotho, Inc. CTPS1 inhibitors and uses thereof
CN113004208A (zh) * 2021-03-08 2021-06-22 沈阳药科大学 一种抑制黄嘌呤氧化酶活性的化合物及制备方法和应用
MX2024005933A (es) * 2021-11-17 2024-08-06 Chdi Foundation Inc Moduladores de htt pata tratar la enfermedad de huntington.
CA3240926A1 (fr) * 2021-12-17 2023-06-22 Sato Pharmaceutical Co., Ltd. Derive d'azaindole inhibant h-pgds
KR20240154607A (ko) * 2022-02-28 2024-10-25 니뽄 다바코 산교 가부시키가이샤 인다졸 화합물 및 그 의약 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2934543A1 (de) * 1979-08-27 1981-04-02 Basf Ag, 6700 Ludwigshafen Substituierte n-benzoylanthranilsaeurederivate und deren anydroverbindungen, verfahren zu ihrer herstellung und ihre verwendung als herbizide
JPH03112985A (ja) * 1989-09-28 1991-05-14 Morishita Pharmaceut Co Ltd Ｎ―（１ｈ―テトラゾール―５―イル）―２―フェニル―５―ピリミジンカルボキシアミド類及びその合成用中間体
GB9405347D0 (en) * 1994-03-18 1994-05-04 Agrevo Uk Ltd Fungicides
JP2000226372A (ja) * 1999-02-01 2000-08-15 Nippon Soda Co Ltd アミド化合物、その製造方法及び農園芸用殺虫剤
JP2002003370A (ja) * 1999-09-20 2002-01-09 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
EP1218336A2 (fr) * 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
MY138097A (en) * 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
JP2003112985A (ja) 2001-10-01 2003-04-18 Nre Happiness Kk 食品残渣肥、飼料原料化システムおよびそれに使用する破砕貯留処理ユニット並びに乾燥冷却処理ユニット
JPWO2004011430A1 (ja) * 2002-07-25 2005-11-24 アステラス製薬株式会社 ナトリウムチャネル阻害剤
CA2494102A1 (fr) * 2002-07-30 2004-02-05 Banyu Pharmaceutical Co., Ltd. Antagoniste de recepteur d'hormone concentrant de la melanine comprenant un derive de benzimidazole en tant qu'ingredient actif
ATE450533T1 (de) * 2003-02-14 2009-12-15 Glaxo Group Ltd Carboxamidderivate
DE60303238T2 (de) * 2003-04-25 2006-09-14 Actimis Pharmaceuticals, Inc., La Jolla Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
JP2007525482A (ja) * 2003-10-07 2007-09-06 レノビス， インコーポレイテッド イオンチャネルリガンドとしてのアミド化合物およびその使用
EP1737414A2 (fr) * 2004-01-23 2007-01-03 Amgen Inc. Ligands du récepteur vanilloide et leur utilisation pour le traitement de douleurs inflammatoires et neuropatiques
PE20110118A1 (es) 2005-10-04 2011-03-08 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds

Also Published As

Publication number Publication date
CR9832A (es) 2008-06-18
EP1937652A1 (fr) 2008-07-02
AU2006299428B2 (en) 2012-04-26
TNSN08104A1 (en) 2009-07-14
JP2009510170A (ja) 2009-03-12
CA2624749C (fr) 2011-08-16
AR056871A1 (es) 2007-10-31
TWI415839B (zh) 2013-11-21
CN101538246A (zh) 2009-09-23
NO20082000L (no) 2008-06-09
PE20070589A1 (es) 2007-06-22
ES2514471T3 (es) 2014-10-28
SG166121A1 (en) 2010-11-29
NZ567208A (en) 2011-03-31
JP5452925B2 (ja) 2014-03-26
IL190411A0 (en) 2008-11-03
US8202863B2 (en) 2012-06-19
CN101282943A (zh) 2008-10-08
IL190411A (en) 2013-09-30
PE20110118A1 (es) 2011-03-08
AU2006299428A1 (en) 2007-04-12
WO2007041634A1 (fr) 2007-04-12
BRPI0616815A2 (pt) 2011-07-05
US20080227782A1 (en) 2008-09-18
EP1937652B1 (fr) 2014-07-30
DOP2006000210A (es) 2007-06-15
UY29840A1 (es) 2007-05-31
CN101538246B (zh) 2014-07-16
MY151172A (en) 2014-04-30
ZA200802222B (en) 2009-09-30
KR101457966B1 (ko) 2014-11-04
UA93213C2 (en) 2011-01-25
KR20080050611A (ko) 2008-06-09
TW200812977A (en) 2008-03-16
ECSP088335A (es) 2008-05-30
CA2624749A1 (fr) 2007-04-12
RU2420519C2 (ru) 2011-06-10
RU2008117170A (ru) 2009-11-10

Similar Documents

Publication Publication Date Title
MA29925B1 (fr) Composes d'amide de pyrimidine en tant qu'inhibiteurs de pgds
MA31326B1 (fr) Pyrimidine-hydrazides en tant qu'inhibiteurs de pgds
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
NO20090910L (no) Sulfonamid-derivater som adrenerge agonister og muskariniske antagonister
MA35285B1 (fr) Indazoles
NO20084005L (no) Aminderivater
WO2005121130A3 (fr) Composes pour le traitement de troubles inflammatoires
PL357555A1 (en) Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
DE602006013493D1 (de) Oxadiazolylpyrazolopyrimidine als mglur2-antagonisten
MA33725B1 (fr) Derives de phenyloxadiazole en tant qu'inhibiteurs de pgds
MA31373B1 (fr) Composes amino-heterocycliques
WO2004033431A3 (fr) Hydroxypyrazoles et methodes prophylactiques ou de traitement de troubles lies au metabolisme
EP1423111A4 (fr) Composes de liaison au recepteur nucleaire fxr nr1h4
MA32798B1 (fr) Acides naphtylacétiques
WO2007146349A3 (fr) Antagonistes du récepteur du cgrp
MXPA05012329A (es) Compuestos utiles para el tratamiento de enfermedades.
WO2006002434A3 (fr) Nouveaux indazole carboxamides et leur utilisation
WO2006055434A3 (fr) Inhibiteurs de la beta-secretase formes d'amines tertiaires macrocycliques pour le traitement de la maladie d'alzheimer
DE602006010540D1 (de) (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl)-amine mit aktivität am 5-ht-rezeptor
GB0407025D0 (en) Novel compounds
WO2005090287A3 (fr) Composes convenant pour le traitement de maladies
TN2009000205A1 (fr) Analogues de pyrazoles
DE602006007483D1 (fr)
WO2007035823A3 (fr) Antagonistes partiels de mglur5 et leurs méthodes d'utilisation
DE602005012826D1 (de) Neue mao-b-hemmer